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ABSTRACT 
Goldstein, Steven A. and Helen Van Vunakls: Determination of fluphenazine, related 
phenothiazine drugs and metabolites by combined high-performance liquid 
chromatography and radioimmunoassay. J. Pharmacol. Exp. Ther. 217: 36-43, 1981. 
Antibodies have been produced in rabbits immunized with a fluphenazine succinate-
human serum albumin conjugate. By radioimmunoassay it is possible to quantify 
fluphenazine (FPZ), related phenothiazine drugs and several of their metabolites at the 
femtomole  level. As little as 370  fmol (160 pg) of FPZ can be detected and up to 0.4 ml 
of plasma can be added to the incubation mixture (final volume = 1 .1 ml). The 
phenothiazine heterocyclic  nucleus is  immunodominant  and determines  the specificity 
of the antiserum. When a parent drug cross-reacts significantly with antibody, its 7-
hydroxide, N-oxide and N-10 side chain altered metabolites can also be determined by 
the assay. The 8-hydroxide, sulfoxide and 7-hydroxyglucuronide metabolites are not 
detectable unless present in large amounts. High-performance liquid chromatography was 
used to separate phenothiazine drugs and metabolites. Since the antiserum has broad 
specificity, a combined high-performance liquid chromatography and radioimmunoassay 
procedure permits the identification and quantification of a phenothiazine drug and its 
serologically reactive metabolites. Patterns of high-performance liquid chromatographic 
elution and extent of immunologic cross-reaction are characteristic for metabolites 
relative to the parent drug. This procedure offers distinct advantages in the analysis of 
this complex family of compounds. FPZ was quantitatively extracted from plasma 
samples obtained from patients receiving FPZ per os. Although large amounts of 
serological activity were present in the samples 2 to 6 hr after FPZ ingestion, only 2 to 
23% was extractable. The major contributors to the serological activity at times greater 
than 6 hr were FPZ metabolites. In a preliminary application of the combined techniques, 
FPZ and a metabolite identified as N-{a-(trifluoro-methylphenothiazinyl-




Phenothiazine neuroleptics are widely prescribed, yet their fate and mechanism of 
action in man have not been clearly elucidated. These drugs are rapidly metabolized to 
numerous products (Usdin, 1971) which possess·¥arying degrees of antipsychotic 
effectiveness (Perel and Manian, 1977). Both the therapeutic and undesirable effects of 
these medications may result from the composite action of the parent drug and its 
metabolites. Attempts to monitor clinical response by measuring drug levels in 
physiological fluids may fail if levels of active metabolites are not determined (Creese et 
al., 1978). Unfortunately, the accurate quantification of drugs and  metabolites is a task 
that has met with limited success. 
Fluphenazine (FPZ) is clinically important because it is potent and long-acting 
when dispensed as an ester in depot formulations (Ayd, 1978). Current techniques with 
adequate sensitivity to determine physiological levels of FPZ include gas 
chromatography (GC)-electron capture detection (Larsen and Naestoft, 1973), GC-
nitrogen/phosphorus sensitive detection (Franklin et al.,1978), gas-liquid chromatography 
(GLC)-nitrogen sensitive detection (Whelpton and Curry, 1976), GLC-electron capture 
detection (Rivera-Calimlin and Siracusa, 1977), ion-pair partition chromatography-UV 
detection (Johansson et al., 1976), high-performance liquid chromatography 
(HPLC)-anodic coulometric detection (Tjaden et al., 1976) and the administration of 
radiolabeled drug (Schreiber and Grozier, 1973; Whelpton and Curry, 1976). High-
performance thin-layer chromatography (HPTLC)-UV reflectance detection (Fenimore et 
al., 1978), GC-mass spectrometry (Alfredsson et al., 1976), formation of fluorescent 
derivatives followed by TLC (Kaul et al., 1972) and formation of radiolabeled derivatives 
followed by selective solvent partition (Efron et al., 1971) have also been used to assay 
phenothiazine drugs in physiological fluids. 
For the most part, these methods can detect only a single drug or an 
undifferentiated total of drug and metabolites. Endogenous biological materials, co-
medications and problems associated with derivitization (Usdin, 1971) have impeded 
quantitative procedures. Although direct radioimmunoassay (RIA) analyses (Shostak, 
1974; Kawashima et al., 1975; Jørgensen, 1978; Sakalis et al., 1978; Wiles and Franklin, 
1978; Midha et al., 1979) avoid some of these problems, they are incapable of 
differentiating between a drug and those serologically reactive metabolities which are 
present in physiological samples. 
In this paper, we report the development of an RIA for FPZ, related 
phenothiazines and several of their metabolites. This assay was used in conjunction with 
an HPLC system devised to separate phenothiazine drugs and metabolites. The combined 
HPLC-RIA technique offers many distinct advantages over previous analytical 
procedures. The technique obviates the need for administration of radiolabeled drugs to 
man, does not require chemical derivitization reactions to achieve adequate sensitivity, 
employs the specificity of an antiserum to overcome interference by endogenous 
compounds that may contribute to measurements carried out by spectral and 
physiochemical procedures, has greater selectivity than direct RIA analyses and allows 
simultaneous determination of a parent compound and its serologically reactive 
metabolites. 
 
Materials and Methods 
 
Table 1 lists the abbreviations used to represent phenothiazine drugs and their 
metabolites. Some of these compounds were generous gifts from the following sources: 
FPZ, FPZ enanthate and FPZ decanoate, Dr. A. Sudilovsky, Squibb Medical 
Laboratories, Princeton, NJ; FPZ-SO, Dr. L.F. Traficante, New York University Medical 
Center, New York, NY; CFaPPP, CFaPPMED, CFaPPHED, CFaPPED and CFaPPA, 
Dr. U. Breyer, Institut fur Toxikologie der Universitat Tiibingen, West Germany; 7-OH-
CPZ, 8-OH-CPZ, 7-MeO-CPZ, CPZ-NO, 7-0Glu-CPZ, 

7-OH-perphenazine, 7-OH-prochlorperazineand 7-OH-triflupromazine, Dr. A. A. 
Manian, National Institute of Mental Health, Rockville, MD; trifluoperazine, 
prochlorperazine, promazine, triflupromazine and thioridazine, Dr. A Mathe, Boston 
University School of Medicine, Boston, MA; CPZ, CPZ-SO and ±flupenthixol, Smith 
Kline and French Laboratories, Philadelphia, PA; perphenazine, Schering Corporation, 
Kenilworth, NJ; protryptiline, Merck Sharp and Dohme, Rahway, NJ; 
imipramine, Ciba Pharmaceutical Company, Summit, NJ; haloperidol, McNeil 
Laboratories, Inc., Fort Washington, PA, [3HJCPZ (49Ci/ mmol), with methyl groups 
labeled, was purchased from Schw11IZ Mann, Orangeburg, NY. [3HJFPZ 
(15.2Ci/mmol), generally labeled, was obtained from the Israeli Atomic Energy 
Commission, Negev, Israel. Fluphenazine acetate wassynthesized by the method of 
Whelpton and Curry (1976). 
1-Ethyl-3-(dimethylaminopropyl)carbodiimide-HCl (CDI) was purchased from 
the Ott Chemical Company, Muskegon, Ml, human serum albumin (HSA) from Miles 
Laboratories, Inc., Elkhart, IN, horse serum from Grand Island Biological Company, 
Grand Island, NY, HPLC grade MeOH from Fisher Scientific Company, Medford, MA. 
All other chemicals were reagent grade and were used without further purification. All 
procedures reported in this study were carried out under muted gold fluorescent lights 
purchased from Sylvania Inc., Danvers, MA. Phenothiazines were stored in the dark at 
0°C. 
Preparation of the conjugate for immunization. FPZ was succinylated at the 
terminal ,8-hydroxyethyl function of the piperazine side chain and covalently linked to 
free primary amino groups of HSA by formation of an amide bond. To FPZ,2HCl (102 
mg, 0.2 mmol) dissolved in 2.0 ml of anhydrous pyridine was added succinic anhydride 
(20 mg, 0.2 mmol) and the reaction mixture allowed to stir overnight at 25°C. An 
additional 25 mg of succinic anhydride was added and stirring continued for 60 min. The 
reaction mixture was applied directly to preparative silica gel plates and separated using 
EtOAc/MeOH/ NILOH, 65:35:11 by volume, as solvent; (FPZ, rr-= 0.70; FPZ succinate, 
rr- 0.39). 
To prepare the conjugate, FPZ succinate (6.5 mg) dissolved in 1 ml of 10% 
aqueous pyridine was added to 25 mg of HSA in 0.1 ml of water (pH adjusted to 7.0). 
CDI (25 mg) was added and the reaction mixture stirred overnight at 25°C. The conjugate 
was separated from unreacted materials by gel filtration on a Sephadex G-50M column 
(35 X 1.5 cm), using saline-phosphate buffer (0.15 M NaCl and 0.005 M 
sodium-phosphate, pH 7.4) as the solvent. Fractions (3 ml) were collected and the 
contents of tubes 12 to 15 were pooled based on optical density measurements. The 
combined fractions were exhaustively dialyzed against the eluting solvent at 4°C. The 
extent of substitution was 20 mol of hapten per mole of HSA as measured by the 
difference in absorbance between solutions of unsubstituted HSA and the conjugate at 
256nm. 
Immunization. Aliquots of the conjugate were emulsified in two volumes of 
complete Freund's adjuvant by a Sorvall Omnimixer at 0°C. Four New Zealand albino 
rabbits were injected i.m. and in toe pads on day 1. All subsequent injections were 
administered i.m. Animals received 1 mg of the conjugate on days 1, 8, 15 and 50 and 2.5 
mg on day 114. Blood drawn on day 122 from one rabbit was used in this study. All 
rabbits produced antibodies that bound the radiolabeled hapten. 
RIA procedure. The antibodies produced to the  FPZ  succinate-HSA conjugate 
bound [3H)CPZ and [3H]FPZ. When these studies commenced only [3H]CPZ of high 
specific activity was available and was used in all experiments unless otherwise noted. 
Separation of free radiolabeled antigen from antibody-bound labeled antigen was 
accomplished by a double antibody technique similar to that used for other assays (Van 
Vunakis and Levine, 1974). All dilutions were made with a 10% horse serum isotris 
buffer (10 ml of horse serum: 90 ml of isotonic Tris buffer-0.15 M NaCl, 0.05 M Tris-
HCl, pH 7.4 at 20°C). 
Performed in duplicate, each assay mixture contained 1.0 ml of buffer, 0.1 ml of a 
standard dilution of inhibitor or of a sample to be analyzed, 0.1 ml ofradiolabeled antigen 
dilution (30,000 dpm/0.1 ml of [3HJCPZ) and 0.1 ml of the immune serum (diluted 
1:500). After incubation for 60 min at 37°C, 0.1 ml of a normal rabbit serum (diluted 
1:25) and 0.1 ml of a goat antirabbit y-globulin (diluted to be in the equivalence zone 
with respect to rabbit y-globulin) were added to each tube. After standing at 4°C for 16 to 
18 hr, precipitates were collected by centrifugation. The supernatant fluid was decanted 
and the walli< of the tubes dried of excess liquid. The precipitates were dissolved in 0.2 
ml of 0.1 N NaOH and 2.8 ml of scintillation fluid {2,5-diphenyloxazole, 5 gm/l, p-bis-
[2-(5-phenyloxazolyl)]-benzene, 0.2 gm/l, BBS-3 (Beckman Instruments, Inc., Fullerton, 
CA) (12% v/v), toluene} was added. The samples were counted in a Packard Tricarb 
model 3320 liquid scintillation counter. When no inhibitor was present, 12,000 dpm were 
precipitated with the immune serum, whereas 300 dpm were precipitated nonspecifically 
in the presence of normal rabbit serum. It is also possible to separate free and antibody-
bound [3HJCPZ by precipitation of the protein with (NIL):$O, (Chard, 1980). 
HPLC. A Waters Associates model 404 LC equipped with a model 440 UV 
detector set at 254 nm, a model 660 solvent programmer and a model U6K pressureless 
injection system were used. A Waters Associates C,s-µBondapack column (0.25 inch 
outer diameter x 1.0 ft) was used for separation of FPZ, related phenothiazines and 
several of their metabolites. A precolumn (0.25 inch outer diameter X 1.6 inch) packed 
with C18-Cor asil was used to protect column integrity. Aqueous solvents for HPLC were 
degassed and then filtered through 0.45 Millipore filters before use. Tlie eluting solvents 
were 0.01 M sodium phosphate, pH 7.4 at 25°C and methanol. The program of elution 
was linear with respect to increasing methanol, 65 to 90% over 20 min. Flow rate was 
constant-at 1.0 ml/min. The  ethylenediamine metabolites  of  FPZ  are retained on the 
column under these conditions. These compounds elute from C1s-µBondapak columns 
when other solvent systems are used: 70% tetrahydrofuran/30% 0.01 M sodium 
phosphate buffer, pH 7.4 at 25°C; or 70% methanol/30% magnesium acetate buffer (9%), 
pH 3.5 at 25°C.  
HPLC-RIA procedure. Fractions collected during chromatographic separation 
were diluted in buffer and analyzed directly by RIA when the concentration of 
serologically reactive material in a sample was high, i.e., greater than 100 pmol of FPZ 
equivalents/ml ofHPLC eluent. Otherwise, samples were dried in a Virtis lyophilizer and 
reconstituted in buffer for assay and storage. 
 
 
Plasma samples. Blood from control subjects wu donated by workers in this 
laboratory. The patient plasma wu from the source previously described (Sakalis et al., 
1978); treatment histories are described in table 2. Plasma (1 ml) wu  diluted with 3 ml of 
H2O in 16 x 150 mm  screw cap culture tubes and  the  pH adjusted  to  9.0 with NaOH. 
n-Heptane (8 ml) containing 2% isoamyl alcohol wu added, and the tubes shaken 
vertically on a mechanical shaker at 200 cycles/min for 20 min  at  4°C. After  
centrifugation for 10 min  at  1500  x g, the organic phase wu    transferred to a second 
tube. The extraction of the aqueous solution wu repeated, and the combined organic 
extracts were dried under nitrogen at 25°C. The residue wu resuspended in 3 ml of 
MeOH (containing 0.1 ml of0.01 N HCl) or horse serum buffer. Twenty-five control 
human plasma samples were supplemented with [3H]FPZ and/or unlabeled FPZ. The 
efficiency of the extraction  procedure  wu 91% for 10 pmol and greater than 95% for 20 
to 66,000 pmol u measured by radioactivity or RIA. Approximately 5% of the  activity 




Sensitivity and accuracy of the RIA. Immunized rabbits produced antibodies with 
sufficiently high affinities to perform the RIA in a buffer containing 10% horse serum. 
This medium served to protect labile phenothiazines from decomposition and reduce their 
adsorption to vessel surfaces. Competitive inhibition of the [ 3H]CPZ- an ti body 
interaction by unlabeled FPZ is described by a standard inhibition curve (fig. 1) that is 
approximately linear from 20 to 80% inhibition, i.e.,0.16 ng (0.37 pmol) to 3.3 ng (7.5 
pmol) of FPZ per incubation tube (logarithmic curve fit correlation r = 0.999). FPZ (0.16 
ng), FPZ enanthate (0.50 ng),  FPZ decanoate  (0.67 ng), perphenazine  (0.025 ng), 
trifluoperazine (0.18 ng), prochlorperazine (0.04 ng), triflupromazine (0.48 ng) and CPZ 
(0.19 ng) were reproducibly detected.  
The intra- and interassay coefficients of variance did not exceed 7.2 and 9.7%, 
respectively, over a concentration range of FPZ which gave 20 to 80% inhibition (fig. 1). 
Within the same concentration range, the amount of FPZ added and the amounts 
measured by RIA correlated quantitatively. 
Identical standard inhibition curves were obtained when FPZ was assayed in the 
presence of 10 µ.l of methanol, 10 µ.l of heptane, 0.1% ascorbic acid as an antioxidant or 
horse serum buffer. Neither endogenous materials in physiological samples nor low 
concentrations of solvents from chromatographic or extraction procedures interfered with 
the antigen-antibody reaction. Assays carried out in the presence of up to 0.4 ml of 
human plasma or 0.1 ml of red blood cell lysate were shown to be independent of both 
FPZ concentration and the amount of sample analyzed. When plasma was assayed 
directly, the limit of detection was 0.93 pmol of FPZ per ml 
Antibody specificity: drugs. The amount of FPZ required to inhibit  the  antibody  




r =    ____________________ 
I50 test compound 
 
is reported for each test compound to facilitate comparison of antibody affinity for 
that compound relative to FPZ and other test compounds, table 1. An r value of 0.1 
indicates that, on a molar basis, the test compound competes only 10% as effectively as 
FPZ for the antibody sites. 
All eight C-2-CF3 and C-2-Cl substituted phenothiazine drugs studied can be 
sensitively quantified by RIA, despite differences in their N-10 side chain structures 
(table 1). Effective inhibition of the  immune reaction is also exhibited by esters of FPZ ( 
i.e., FPZ decanoate,  r = 0.32)  and  by those drugs with  N-10 side chain groups less 
complex than that of FPZ ( i.e., triflupromazine, r = 0.27) or perphenazine (i.e., CPZ, r = 
0.63). 
Differences in specificity are observed for drugs containing identical alkylamino 
side chains but different substituents at position 2 of the aromatic nucleus. Antibody 
binding of Cl rather than CF3 substituted drugs is slightly favored, whereas diminished 
binding of an  unsubstituted analog is observed, i.e., CPZ (r  = 0.63), triflupromazine (r-= 
0.27) and promazine (r = 0.036). 
Among those compounds which differ from FPZ in the structure of  their tricyclic 
nucleus,  ±flupenthixol  is bound only 5-fold less effectively than FPZ, although olefinic 
carbon replaces the  N-10 nitrogen. Imipramine (r = 0.077) and protryptiline (r = 0.013), 
each with a seven-membered central ring, are also bound with marked avidity when 
compared to promazine ( r = 0.036). Haloperidol, dopamine and  
o-trifluoromethylaniline ex-hibit no inhibition at concentrations greater than 15 nmol ( r < 
0.0002). 
Antibody specificity: metabolites. The cross-reactivities of metabolites follow 
consistent trends. Biotransformation of N-10 side chain structures does not significantly 
alter antibody affinities (table 1). Metabolites of FPZ (Breyer et al., 1974a,b) which  
result from dealkylation of its  N-10  P-hydroxyethylpi-perazine side chain are effective 
inhibitors of the immune reaction: CFaPPP (r = 0.91), CFaPPHED (r = 0.63), CFaPPED 
(r  = 0.50), CFaPPA  (r  = 0.56)  and CFaPPMED  (r  = 0.19). Oxidation of nitrogen in 
the N-10 dimethylamino side chain of CPZ yields another effective inhibitor, CPZ-NO (r 
= 3.8). 
Metabolites which 1 tlt from oxidation of the heterocyclic nucleus show decreasea 
antibody affinities, as exemplified by CPZ and its metabolites (fig. 1): CPZ (r = 0.63), 7-
OH-CPZ (r =  0.15)  > 8-OH-CPZ  (r  =  0.009),  CPZ-SO  (r  =  0.001)  and 7-OGlu-CPZ   
(r   <  0.0001).  Hydroxylation  of  position  7  yields metabolites which inhibit 4- to 11-
fold less effectively than their unoxidized congeners. The 7-hydroxyglucuronide and the 
sulfoxide metabolites, considered to be pharmacologically inactive (Creese et al., 1978; 
Dutton et al., 1977), are bound weakly by the antibodies. 
Interaction of the [3H]CPZ preparation with a subset of antibodies in the 
antiserum can explain the observation of greater avidity for C-2-Cl rather than C-2-CF3 
substituted compounds. However, when [3H]FPZ became available and was used for 
RIA, only minor changes in specificity and sensitivity resulted. Determined r values 






Fig. 1. Inhibition of the [3H)CPZ and FPZ succinate-HSA antibody reaction by FPZ, 
CPZ and CPZ metabolites. The FPZ inhibition curve represents  the 11ean ± S.D. for five 
independent determinations. The RIA was performed as described under "Materials and 
Methods.'' 
 
Separation of phenothiazines by HPLC. Reverse phase HPLC effectively 
separates a phenothiazine drug and its derivatives (table 1). Elution order is primarily a 
function of compound polarity. Compounds with identical C-2-CFJ tricyclic nuclei show 
the effect of N-10 side chain moieties on elution volumes (milliliters): FPZ (20.3), 
CFJPPA (24.4), trifluoperazine (26.5), triflupromazine (27.2), FPZ enanthate (29.1), 
CFJPPP (29.4) and FPZ decanoate (35.0). 
Patterns of elution for metabolites which result from oxidation are shown by the 
CPZ series: 7-0Glu-CPZ (7.5), CPZ-NO (15.5), CPZ-SO (19.8), 7-OH-CPZ (22.2), 8-
OH-CPZ (22.4) and CPZ (28.4). All derivatives resulting from hydroxylation of positions 
2, 7 or 8 elute in volumes 70 to 80% as great as their unoxidized parent compound (table 
1). 
Carbon 2 substituents had little effect on the retention of those compounds 
available for study. This is shown by the N-10-propyldimethylamino side chain series, C-
2-CF3 (triflupromazine, 27.2), C-2-H (promazine, 27.5) and C-2-Cl (CPZ, 28.4). 
HPLC-RIA procedure. Figure 2 shows the separation of FPZ, FPZ-SO, FPZ 
enanthate, CFJPPA and CFJPPP by HPLC and their quantification by RIA. The results 
are expressed as FPZ equivalents, since the percent inhibition of the [3H]CPZ-antibody 
reaction by serologically reactive materials was related to the standard inhibition curve 
obtained for FPZ. To obtain the absolute quantity of a test compound, the percent 
inhibition can be related to a standard inhibition curve constructed with known amounts 
of test compound, or the appropriate r value at Iso can be used (table 1). The r values can 
also be used to obtain estimates of absolute quantities of test compounds at levels of 
inhibition other than 50%, since standard inhibition curves for FPZ and test compounds 
are approximately parallel from 20 to 80% inhibition. 
When control human plasma samples were extracted and analyzed by the HPLC-
RIA procedure, no serological activity was observed, indicating that neither endogenous 
materials nor solvent residues interfered with the assay. When FPZ was applied to the 
column (2.5-14,200 pmol), greater than 95% was recovered, and serological activity 
emerged only at the position expected of the FPZ peak. In the overall procedure (i.e., 
extraction, HPLC and RIA), recoveries of FPZ were greater than 90%. When these 
samples were analyzed in an unrelated im-mune system (i.e., continine-anticotinine; 
Langone et al.,1973), no serological activity was observed. 
Disposition of FPZ in plasma. The organic and aqueous phases resulting from 
extraction of plasma samples by the procedure shown to remove essentially all FPZ were 
analyzed by RIA. Although large amounts of serological activity were present in all 
plasma samples from patients who had ingested FPZ •2HC1 2 to 6 hr earlier, only 2 to 
23% was extractable and could have been unaltered FPZ (table 2). 
 
 
Fig. 2.  HPLC-RIA  analysis <•>. with spectral trace (-), of FPZ and four  of its  
derivatives.  A solution (50 µI) containing  FPZ (0.82 nmol), FPZ-SO (0.80 nmol), FPZ 
enanthate (0.45 nmol), CF3PPA(1.20 nmol) and CFaPPP (0.52 nmol) was applied to the 
column. Fractions of eluent were collected, lyophilized, reconstituted in horse serum 
buffer and analyzed by the RIA, as described under  "Materials and Methods." 
N.D. signifies less than 0.37 pmol of FPZ equivalents. Elution volumes are not identical  
to those reported in  table 1 because a  different  C18-µBondapak column and a linear 
gradient (70  to  100% methanol/0.01 M sodium phosphate, pH 7.4 at 25°C) was used. 
Although absolute elution volumes vary with different C,.,-µBondapak columns, the 
relative pattern of elution of a parent compound and its derivatives remains unaltered. 
The organic phase from one plasma extract was subjected to HPLC-RIA analysis 
(Patient F', t = 2-6 hr, fig. 3). The complexity of the absorbance profile obtained was 
characteristic of extracts of plasma samples from patients and control subjects. 
Contribution by unrelated compounds to absorbance measurements precluded accurate 
quantification of FPZ or its metabolites by spectral analyses. However, RIA analysis of 
eluent fractions showed that at least 96% of the serological activity present in the organic 
phase could be accounted for by materials which eluted in three regions of the 
chromatogram (i.e., 78 pmol of FPZ equivalents were recovered of 81 pmol of FPZ 
equivalents applied to the column). 
Region A (3-8 ml) was heterogeneous (fig. 3). Peak B had an elution volume 
identical to FPZ, and the identity of this compound was confirmed by co-elution with 
labeled and unlabeled drug. Peak Chad an elution volume identical to CFJPPP. Peak C 
was also found to accumulate as a metabolic product of in vitro metabolism of [3H]FPZ 
by rat liver microsomes. In the latter experiments, sufficient quantities of this material 
were isolated by chromatography to study its absorbance characteristics, cross-reactivity 
with antibody and radioactivity content. An r value of 0.91 was determined for the 
isolated material by comparing the FPZ equivalents assessed by RIA and levels 
calculated from absorbance measurements. This supports the tentative identification of 
peak C as CFaPPP (CF3PPP, r = 0.91, table 1). Similar metabolic profiles were observed 
in analyses of plasma samples from two other high dose patients. The chromatogram 
from one patient contained additional serologically active peaks which eluted separately 
in 24, 34 and 60 ml of solvent, respectively. 
Equilibrium dialysis of the aqueous phase (Patient F') against normal human 
plasma showed that 96% of the serologically active materials were dialyzable and, 
therefore, FPZ metabolites do not appear to be covalently bound to plasma constituents. 
HPLC-RIA analysis of materials isolated from the aqueous phase by equilibrium dialysis 
against water showed serological activity. only in region A of the chromatogram. 
Preliminary studies suggest that a portion of these isolated materials are conjugates of 
FPZ and its metabolites. 
Plasma samples from patients receiving both low and high doses of FPZ-2HC1 
were studied in order to facilitate development of the HPLC-RIA methodology. The 
parameters outlined above indicate that determinations of phenothiazine drugs and their 
known metabolites, present in samples from patients receiving commonly administered 














FPZ equivalents (Eq) In plasma samples of patients receiving the drug • 
 
• Plasma samples were extracted, dried, reconstituted and analyzed by RIA, as 
described under ""Materials and Methods." 
• Alter one week of placebo, samples were drawn from all patients before (I - Ohr) and 
alter (I - 2-6 hr) 25 mg of FPZ·2HCI had been administered orally (Sakalls et a/., 
1978). Plasma samples from Patient F were also drawn on day 28 of therapy (F'), 
before and alter 250 mg of FPZ-2HCI had been administered orally. Patient F 
received 25 mg t.i.d., increased progressively in 2 weeks to a maintenance dose of 
250 mg t.l.d. 
c N.D., <0.37 pmol of FPZ Eq/0.4 ml of plasma. 
 
Fig. 3. HPLC-RIA analysis (•). with spectral trace (--),of an extracted plasma sample 
(organic phase). An aliquot (125 µI, 81.25 pmol of FPZ equivalents) of the plasma 
extract (Patient F', t - 2-6 hr), reconstituted in MeOH/0.01 N HCI, was separated by 
HPLC and analyzed by RIA, as described under "Materials and Methods.·· For 
identification of serologically active materials quantified, see text. N.D. signifies less 
than 0.37 pmol of FPZ equivalents. 
Discussion 
 
Rabbits immunized with the FPZ succinate-HSA conjugate produced antibodies 
with specificities directed primarily toward the heterocyclic nucleus of the hapten. RIA 
allowed sensitive quantification of eight phenothiazine drugs and many of their 
metabolites After they had been separated by HPLC. The combined HPLC and RIA 
procedure can separate, identify and quantify a single compound, or simultaneously 
monitor several, in extracts of physiological samples. It was first used to determine 
individual compounds in complex mixtures of closely related metabolites by Langone et 
a/,. (1975). Such a procedure is needed for clinical and experimental studies of the 
phenothiazine neuroleptics. Thirty metabolites of CPZ have been identified (Usdin, 
1971), and derivatives of FPZ may be more numerous (Breyer et al.,1974b). 
Attempts to accurately quantify individual phenothiazirie compounds in 
physiological samples by direct RIA have achieved only limited success. Broadly 
reactive antisera have been produced despite the use of several different immunizing 
conjugates. The complex metabolism and lability of these drugs have compounded the 
problem. When direct RIA determinations have been conducted to assess parent drug 
levels, immunoreactivity was found in plasma samples for days after drug administration. 
However, no independent method was used to confirm the contention that the measured 
activity was due solely to the parent drug (Kawashima et al., 1975; Jørgensen, 1978; 
Wiles and Franklin, 1978; Midha et al., 1979; Wiles and Gelder, 1980). 
While peak concentrations of serological activity are present in plasma samples 
obtained from patients 2 to 6 hr after FPZ ingestion (Sakalis et al., 1978), we have shown 
that only 2 to 23% of the activity can be attributed to unaltered FPZ. Unidentified FPZ 
metabolites that are not extractable from plasma samples at pH 9.0 are the major 
contributors to the serological activity. 
In a previous report (Sakalis et  al., 1978), our RIA was used to assess possible 
correlations between total immunoreactivity in plasma samples and clinical response in 
patients ingesting FPZ. A direct relationship between dose and plasma level was 
observed, but no relationship between plasma level and clinical response or 
extrapyramidal side effects could be established. Recently, a positive correlation between 
plasma immunoreactivity (as detected by another direct RIA for FPZ) and prolactin levels 
was obtained in patients receiving FPZ (Wiles and Gelder, 1980). It was suggested, 
therefore, that circulating FPZ and its active metabolites had been estimated. However, 
unless a fortuitous relationship exists between the physiological activities of drugs and 
metabolites and their antibody affinities, direct RIA analysis cannot provide an accurate 
estimate of pharmacologically active compounds or yield a value which is necessarily 
relevant to a measurable effect. Without the benefit of an independent method to establish 
the identity of assayed materials, the significance of serological activity measured by 
analyzing physiological samples directly by RIA remains unclear. 
It has been postulated that clinical response to neuroleptic drugs may be predicted 
by detection of those compounds which compete with [3H]haloperidol in binding to 
dopamine receptor preparations (Creese et al., 1978). To measure effective dose levels by 
any method and study their correlation with patient response, it will be necessary to 
identify physiological samples which reflect levels of parent drug and active metabolites 
at their active sites (cf., Perel and Manian, 1977). 
Whelpton and Curry (1976) identified FPZ, FPZ-SO and 7- OH-FPZ primarily as 
conjugates in urine, free FPZ and 7-OH-FPZ in feces, but only unmetabolized FPZ and 
the ''virtual absence" of conjugates in the plasma of a patient receiving [14C]-FPZ. These 
compounds have also been identified as excretion products in urine, feces or bile of dog 
and rhesus monkey, after [ 14C]FPZ or [14C]FPZ enanthate was administered (Dreyfuss 
et al., 1971). The excretion of CFaPPA-80 in the urine o human, rat and dog (Breyer et 
al., 1974a) and tissue accumulation of CFaPPP, CFaPPMED, CFaPPED and CFaPPHED 
in rats receiving FPZ (Breyer et al., 1974b) have also been reported. 
In preliminary analyses by the HPLC-RIA procedure of plasma samples from 
patients receiving high doses of FPZ• 2HCl, we have found evidence that FPZ and 
CFaPPP constitute a minor extractable fraction of the total serologically active materials 
present. The major portion of the serological activity in plasma samples from patients 
receiving either high or low doses of FPZ remains in the aqueous phase. The fact that 
such unidentified metabolites are immunologically reactive can facilitate their detection. 
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